Dr. Mott Discusses Targeted Therapy for ALK+ NSCLC | OncLive

Dr. Mott Discusses Targeted Therapy for ALK+ NSCLC

November 3, 2017

Frank E. Mott, MD, FACP, department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses taregeted therapy for ALK-positive non-small cell lung cancer (NSCLC).

Frank E. Mott, MD, FACP, department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses taregeted therapy for ALK-positive non-small cell lung cancer (NSCLC).

ALK-positive tumors represent 2% to 4% of NSCLC. There are new data demonstrating that patients respond much better to chemotherapy, states Mott.

According to Mott, newer agents, such as alectinib (Alcensa), are showing durable responses and progression-free survival for patients with central nervous system (CNS) metastases.


x